NCT07213076View on ClinicalTrials.gov

Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

RecruitingOBSERVATIONAL

Enrollment

350

Participants

Timeline

Start Date

July 4, 2025

Primary Completion Date

November 10, 2025

Study Completion Date

November 10, 2025

Conditions

Non-small Cell Lung Cancer

Trial Locations (1)

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Peter MacCallum Cancer Centre, Australia

OTHER

lead

AstraZeneca

INDUSTRY